community-acquired

Moxifloxacin hydrochloride (BAY12-8039 HCl) is a fourth generation fluoroquinolone with expanded activity against gram-positive bacteria as well as atypical pathogens. Moxifloxacin has been linked to mild ALT elevations during therapy and to rare instances of idiosyncratic acute liver injury with symptoms and jaundice.

Faropenem sodium is an orally bioavailable penem antibiotic effective in treating Mycobacterium tuberculosis, as well as tuberculosis and community-acquired pneumonia.

Omadacycline (Amadacycline), a new tetracycline antibiotic, can inhibit the 30s subunit of bacterial ribosome.

Decarboxy Moxifloxacin is a decarboxylated compound of moxifloxacin. Moxifloxacin is an oral active 8-methoxyquinolone antibiotic used in acute bacterial sinusitis, chronic bronchitis, acute bacterial deterioration, and community-acquired pneumonia.

Avarofloxacin (JNJ-Q2) is a broad-spectrum fluoroquinolone antibacterial drug under development for treating acute bacterial skin and skin structure infections, as well as community-acquired pneumonia.

Lefamulin acetate (BC-3781 acetate) (formally BC-3781 acetate) is a novel pleuromutilin antibiotic and is the first to be used for the systemic treatment of bacterial infections in humans. Lefamulin acetate (BC-3781 acetate) inhibits protein synthesis by binding to the peptidyl transferase center of the 50S bacterial ribosome, preventing the binding of transfer RNA for peptide transfer. Lefamulin acetate (BC-3781 acetate) is an orally active antibiotic for community-acquired bacterial pneumonia (CABP) treatment.

Nafithromycin (WCK 4873) serves as an orally administered antibiotic effective against community-acquired pneumonia organisms such as Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and Methicillin-susceptible Staphylococcus aureus. It displays a minimum inhibitory concentration (MIC 90) of 0.12 mg liter against both macrolide-resistant and telithromycin-insensitive Streptococcus pneumoniae.

Cefdinir is an advanced broad-spectrum cephalosporin antibacterial compound approved for treating community-acquired pneumonia, acute bacterial exacerbations of chronic bronchitis, acute maxillary sinusitis, pharyngitis tonsillitis, acute bacterial otitis media, and uncomplicated skin and skin structure infections in both adult and pediatric patients.

Acorafloxacin is a broad-spectrum fluoroquinolone antibacterial drug being developed for the treatment of acute bacterial skin and skin structure infections and community-acquired pneumonia.

TP-271, a tetracyclines antibiotic, is used potentially for the treatment of community-acquired bacterial pneumonia (CABP).

Grepafloxacin (OPC-17116) is a fluoroquinolone antibiotic that is administered orally. It possesses strong efficacy against community-acquired respiratory pathogens, notably Streptococcus pneumonia. Grepafloxacin exhibits excellent tissue penetration and demonstrates a promising pharmacodynamic profile.

Lanopepden, also known as GSK-1322322 or GSK-322, is a potent and selective peptide deformylase inhibitor with good in vitro activity against bacteria associated with community-acquired pneumonia and skin infections. GSK1322322 had bactericidal activity against S. pneumoniae, H. influenzae, S. pyogenes, and S. aureus, demonstrating a ≥ 3-log(10) decrease in the number of CFU ml at 4× MIC within 24 h in 29 of the 33 strains tested. GSK1322322 represents a valuable alternative therapy for the treatment of infectious diseases caused by drug-resistant pathogens.

Omadacycline, also known as PTK 0796 and Amadacyclin, is a novel first-in-class aminomethylcycline with potent activity against important skin and pneumonia pathogens, including community-acquired methicillin-resistant Staphylococcus aureus (MRSA), β-hemolytic streptococci, penicillin-resistant Streptococcus pneumoniae, Haemophilus influenzae, and Legionella. Omadacycline is active against strains expressing the two main forms of tetracycline resistance (efflux and ribosomal protection). The primary effect of omadacycline is on bacterial protein synthesis, inhibiting protein synthesis with a potency greater than that of tetracycline. The binding site for omadacycline is similar to that for tetracycline.

Zifanocycline (KBP-7072), a third-generation semisynthetic aminomethylcycline antibiotic, inhibits bacterial ribosome function, displaying broad-spectrum antibacterial activity in vitro against both Gram-positive and Gram-negative bacteria, notably multidrug-resistant strains. It is formulated for oral and injectable use, targeting research on acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, and complicated intra-abdominal infections [1] [2].

Ceftaroline fosamil hydrate acetate is a powerful cephalosporin antibiotic that exhibits broad-spectrum efficacy against both Gram-positive pathogens, such as methicillin-resistant Staphylococcus aureus (MRSA) and multidrug-resistant Streptococcus pneumoniae, and common Gram-negative bacteria. It possesses anti-infective properties suitable for studying complicated skin and skin structure infections (cSSSIs) and community-acquired bacterial pneumonia (CABP) [1] [2] [3].

Nemonoxacin (TG-873870) is an orally available non-fluorinated quinolone antibiotic with broad-spectrum antimicrobial activity against staphylococci, streptococci, and enterococci, as well as against Neisseria gonorrhoeae and Haemophilus influenzae.Nemonoxacin is used in the study of bacterial infections and community-acquired pneumonia.

Cefetamet, a cephalosporin antibiotic, shows potential for researching upper and lower community-acquired respiratory tract infections [1].

Zifanocycline (KBP-7072) TFA is a semi-synthetic aminomethylcycline antibiotic with oral bioavailability that targets bacterial ribosomes to impede their function. Displaying a broad spectrum of in vitro antimicrobial efficacy, it combats both Gram-positive and Gram-negative bacteria, including numerous multidrug-resistant strains. Clinical investigations focus on treating acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, and complicated intra-abdominal infections [1] [2].

Faropenem-d7 Sodium Salt is a deuterated compound of Faropenem Sodium Salt. Faropenem Sodium Salt has a CAS number of 122547-49-3. Faropenem sodium is an orally bioavailable penem antibiotic which can efficiently kill Mycobacterium tuberculosis.It treatment of tuberculosis and community-acquired pneumonia.